Navigation Links
Geneticure Awarded Patent for Precision Medicine Blood Pressure Treatment
Date:9/17/2019

Geneticure, Inc., a Rochester Minnesota company developing personalized medicine tests to improve success in chronic diseases, announces today that the U.S. Patent and Trademark Office (USPTO) and European Patent Office (EPO) have issued patents for their multi-gene combinatorial genetic algorithm to rank drug class recommendations for hypertension treatment.

The patent applies to Geneticure’s first pharmacogenomics test, in a pipeline that includes additional chronic disease panels. The Geneticure for Hypertension Pharmacogenomic Panel is the first of its kind to use multiple gene variants that have been weighted according to their impact on blood pressure response and include integration across organ systems and medication response.

The initial algorithm was formulated using a candidate-gene approach from hundreds of peer-reviewed studies that identify how subtle variations in the genetic code can influence which blood pressure medication will work most effectively, and with original research. The effectiveness of Geneticure’s assay was then assessed an optimized in multiple retrospective clinical trials that have demonstrated that a patient who is prescribed the medication ranked as the first recommendation by the algorithm had significantly lower blood pressure than a patient who did not match the recommendation.

“This is a major milestone for our company solidifying our unique cornerstones of personalized medicine: expertise in the genomics of integrative physiology, leading with powerful clinical and health economic evidence while coupled with strong intellectual property,” said Scott Snyder, co-founder and CEO of Geneticure.

About Geneticure: Geneticure Inc. is a leading personalized medicine company dedicated to the promise of using an individual’s genetics to help guide their treatment. Geneticure’s proprietary approach leverages a unique understanding for the integrative physiology in complex and chronic diseases. This allows Geneticure’s tests to be tailored for each specific disease and the underlying genetics influential to treatment response. An evidence-first company, Geneticure focuses on clinical research demonstrating improved outcomes and improved health-economics, supporting the shift from one-size-fits-all medicine to precision medicine. For more information, visit http://www.geneticure.com.

Read the full story at https://www.prweb.com/releases/geneticure_awarded_patent_for_precision_medicine_blood_pressure_treatment/prweb16575176.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology technology :

1. S&D Marketing Advertising Awarded WBENC Certification
2. Boston Heart Diagnostics Awarded $450,000 in Tax Incentives from the Massachusetts Life Sciences Center
3. Cellular Dynamics and Coriell Institute for Medical Research Awarded Multi-Million Dollar Grants from California Institute for Regenerative Medicine to Manufacture and Bank Stem Cell Lines
4. BioPharm Insight Journalist Awarded Fellowship by Association of Health Care Journalists
5. Selenium, Ltd. Awarded $500,000 SBIR Grant for Biofouling Prevention Technology
6. Nanotherapeutics Awarded Defense Department Contract for Advanced Development and Manufacturing of Medical Countermeasures
7. Provitro Biosciences Awarded First-Ever U.S. Patent For Large-Scale Production Of Bamboo Plants
8. Empire Genomics Awarded SBIR Phase I Grant from NCI for Companion Diagnostics for Multiple Myeloma
9. University of Huddersfield awarded £93k award from the EPSRC
10. Puritan Awarded New Canadian Patent for PurFlock® Ultra Flocked Swab
11. ConfometRx Awarded Patent on GPCRs that Contain a Stabilizing IC2 Fusion Protein
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2019)... ROCKVILLE, Md. (PRWEB) , ... October 09, 2019 ... ... Thursday, October 10th, groups of Montgomery County middle school and high school students ... to handle stressors, utilize relaxation techniques and physical fitness, and apply lifelong social/interpersonal, ...
(Date:10/8/2019)... BOSTON (PRWEB) , ... October 08, 2019 , ... Today, ... U.K. of its lead development technology. Like the company’s precursor patent, approved in ... and accurate counting of tissue stem cells. Asymmetrex now markets the technology in ...
(Date:10/3/2019)... ... ... eKare’s inSight® digital 3D imaging and wound measurement system has been selected ... Health Science Network (EMAHSN), the innovation arm of the NHS. The program was designed ... and deploy solutions to the most pressing challenges facing the NHS. , The ...
(Date:9/24/2019)... ... 2019 , ... Drug resistance has been declared as one of the biggest ... one of the most serious concerns. Hong Kong cannot be spared from the worsening ... or a seven-fold of the figure in 2007 – the year the disease became ...
Breaking Biology Technology:
(Date:9/25/2019)... ... 25, 2019 , ... Deep Science Ventures (DSV), a new paradigm ... independent funder of cancer research. , Deep Science Ventures was founded to create a ... the opportunity from the start, both at the industry and biological level. , ...
(Date:9/24/2019)... SEATTLE (PRWEB) , ... September 24, 2019 , ... ... pharmaceutical companies characterize protein interactions for accelerated drug development, announced today that it ... round was led by OS Fund and also includes AME Cloud Ventures, Boom ...
(Date:9/17/2019)... ... September 17, 2019 , ... VISTAAR released ADVISORY Playbooks to help ... re-assurance / 2nd opinion to their internal strategies they formed for developing or launching ... into new markets, or planning to change their product elements and want to know ...
Breaking Biology News(10 mins):